■帕金森病(PD)以多巴胺能神经元的炎症为代表,导致各种炎症介质的释放。这些介质激活转录因子NF-κB,进而激活诱导型一氧化氮合酶(iNOS),导致炎症增加。
■本研究旨在研究芒果苷的组合效果,具有低剂量一氧化氮(NO)调节剂的NF-κB特异性抑制剂。
■每组共使用8只体重为200-250g的Wistar大鼠。进行立体定向手术以诱导6-羟基多巴胺(6-OHDA)病变。治疗期从第14天延长至第42天,在此期间进行行为测试以评估芒果苷及其与NO调节剂的组合的作用。在第42天,取出大鼠的大脑用于生化和分子分析。
■芒果苷显著提高了6-OHDA损伤大鼠的运动活性并降低了炎性趋化因子水平。芒果苷治疗降低了髓过氧化物酶(MPO)水平并降低了氧化应激。特别是,芒果苷处理后,caspase-3,caspase-9和COX-2活性显着降低。45µg芒果苷和10mg/kgL-NAME的组合显示运动能力的最大改善,行为,生物化学,和6-OHDA损害的分子参数。
■在这项研究中,发现芒果苷通过抑制引起炎症的趋化因子如TNF-α和IL-6来保护具有6-OHDA病变的大鼠。此外,10mg/kg剂量的iNOS抑制剂L-NAME与45µg芒果苷的分组增强了芒果苷的抗炎和抗帕金森病活性。因此,芒果苷和L-NAME的联合治疗有望用于PD的治疗。然而,需要进行临床试验来评估这种联合疗法在人体中的疗效.
UNASSIGNED: Parkinson\'s disease (PD) is typified by inflammation of dopaminergic neurons leading to the release of various inflammatory mediators. These mediators activate the transcription factor NF-κB, which in turn activates inducible nitric oxide synthase (iNOS), leading to increased inflammation.
UNASSIGNED: This study was intended to study the effect of combination of mangiferin, a specific inhibitor of NF-κB with low-dose nitric oxide (NO) modulators.
UNASSIGNED: A total of eight Wistar rats weighing 200-250 g were used in each group. Stereotactic surgery was performed to induce 6-hydroxydopamine (6-OHDA) lesions. The treatment period extended from day 14 to day 42, during which time behavioral tests were performed to evaluate the effects of mangiferin and its combination with NO modulators. On day 42, the brains of the rats were removed for biochemical and molecular analyzes.
UNASSIGNED: Mangiferin significantly improved locomotor activity and decreased inflammatory chemokines levels in rats with 6-OHDA lesions. Mangiferin therapy decreased myeloperoxidase (MPO) levels and reduced oxidative stress. In particular, caspase-3, caspase-9 and COX-2 activities were significantly reduced after the mangiferin treatment. A combination of 45-µg mangiferin and 10-mg/kg L-NAME showed the greatest improvement in locomotor, behavioral, biochemical, and molecular parameters impaired by 6-OHDA.
UNASSIGNED: In this study, mangiferin was found to protect rats with 6-OHDA lesions by inhibiting inflammation causing chemokines such as TNF-α and IL-6. Besides, the grouping of iNOS inhibitor L-NAME at a dose of 10 mg/kg with 45-µg mangiferin enhanced the anti-inflammatory and anti-Parkinsonian activity of mangiferin. Consequently, the combination therapy of mangiferin and L-NAME is promising for the treatment of PD. However, clinical trials will be required to evaluate the efficacy of this combination therapy in humans.